• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem, Inc. - Common Stock (NQ:VSTM)

    5.270 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1
    Open 5.270
    Bid (Size) 5.170 (1)
    Ask (Size) 5.270 (7)
    Prev. Close 5.270
    Today's Range 5.270 - 5.270
    52wk Range 2.100 - 9.100
    Shares Outstanding 44,784,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire

    Performance

    YTD
    -18.8%
    -18.8%
    1 Month
    +14.1%
    +14.1%
    3 Month
    -25.1%
    -25.1%
    6 Month
    -2.2%
    -2.2%
    1 Year
    +54.1%
    +54.1%

    More News

    Read More
    Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
    Via FinancialNewsMedia
    Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
    From FN Media Group LLC
    Via GlobeNewswire
    Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
    From Verastem Oncology
    Via Business Wire
    Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
    Via Stocktwits
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
    Via Benzinga
    What's Going On With Verastem Oncology Stock On Monday?
    Via Benzinga
    Which stocks are experiencing notable movement on Monday?
    Via Chartmill
    Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at the Jefferies Global Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
    Via Benzinga
    Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
    Via Stocktwits
    FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces $75 million Private Placement
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
    From Verastem Oncology
    Via Business Wire
    9 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
    From Verastem Oncology
    Via Business Wire

    Frequently Asked Questions

    Is Verastem, Inc. - Common Stock publicly traded?
    Yes, Verastem, Inc. - Common Stock is publicly traded.
    What exchange does Verastem, Inc. - Common Stock trade on?
    Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verastem, Inc. - Common Stock?
    The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
    What is the current price of Verastem, Inc. - Common Stock?
    The current price of Verastem, Inc. - Common Stock is 5.270
    When was Verastem, Inc. - Common Stock last traded?
    The last trade of Verastem, Inc. - Common Stock was at 07/22/25 04:00 PM ET
    What is the market capitalization of Verastem, Inc. - Common Stock?
    The market capitalization of Verastem, Inc. - Common Stock is 236.01M
    How many shares of Verastem, Inc. - Common Stock are outstanding?
    Verastem, Inc. - Common Stock has 236M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.